Bavarian Nordic secures four-year UK vaccine supply deal
MVA-BN is indicated for use in individuals from the age of two years considered at smallpox or mpox infection risk.
Therapy Area
Pelthos and Castle Creek plan merger to target skin diseases
Podcast: ESMO26: Major readouts from the 2026 congress
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
